The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
Oxford, UK, 2 May 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection ('CDI'), announces the online publication of results from the Company's Phase 2 clinical trial, called CoDIFy, in The Lancet Infectious Diseases. CoDIFy evaluated the Company's novel antibiotic for the treatment of CDI, ridinilazole, against standard of care, vancomycin. The results showed ridinilazole demonstrated substantial clinical benefit over vancomycin. This included ridinilazole achieving statistical superiority over vancomycin in sustained clinical response ('SCR'), a composite endpoint of cure at the end of treatment and no recurrence 30 days after treatment, a result which was driven by a large numerical reduction in infection recurrence.
Oxford, UK; 3rd May 2017 – Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focusing on neurodegenerative diseases, today announced that it has appointed Dr. Robert Haigh as its new Chief Operating Officer. Dr. Haigh has more than 25 years of senior management and board level experience in pharmaceutical and biotech companies across Europe and the US. He joins Neuro-Bio from KalVista Pharmaceuticals Ltd, a company he co-founded in 2011 and where he served as COO before the company’s recent merger with Carbylan Therapeutics.
We live in an age of change where technology is allowing markets to move with breathtaking speed. Radical disruption is now a given. Companies that fail to expect and embrace it are left behind. Global brands that have grown spectacularly in recent years – such as AirBnB and Uber – have come from nowhere to transform entire sectors with their revolutionary approaches. Their ability to innovate – in terms of both products and the business model – has provided food for thought and inspiration for CEOs in every sector, including those attending BioTrinity this week.
UK businesses can apply for a share of up to £12 million to develop innovative ideas that will help solve healthcare challenges.
Oxford, UK Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focussingon neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013. The innovative Neuro-Bio technology is the result of over 40 years of basic research by Baroness Professor Susan Greenfield's group, initially at Oxford University, that points to a previously unidentified mechanism underlying the continuing cycle of cell death that characterises the neurodegenerative process. The company has been exploring whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.
Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and Scottish Investment Bank (the investment arm of Scottish Enterprise) totalling £1.2 M. The funding will be used to develop ELN-21 and ELN-22, the companies’ next generation biologics for topical treatment of ocular disease.
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national T-SPOT®.TB test positivity rates within the United States and United Kingdom, as well as a grant to support TB screening for high risk patients.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.